Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated (0I3Q.L) Stock Overview
Explore Corcept Therapeutics Incorporated’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
7.4B
P/E Ratio
55.18
EPS (TTM)
$0.91
ROE
0.20%
0I3Q.L Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Corcept Therapeutics Incorporated (0I3Q.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 47.34, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $104.32.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 55.18 and a market capitalization of 7.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.